- Janssen received European approval for DARZALEX® (daratumumab) subcutaneous formulation in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed systemic light-chain (AL) amyloidosis, based on data from the Phase 3 ANDROMEDA study -
- Janssen also received approval for DARZALEX® SC in combination with pomalidomide and dexamethasone for adult patients with relapsed or refractory multiple myeloma, based on the Phase 3 APOLLO study -
PR Newswire
SAN DIEGO, June 22, 2021